Multimodal profiling of Pepcan-CB1 receptor structure-activity relationships: integrating molecular dynamics simulations, biological profiling, and the deep learning model MuMoPepcan
Hongyang Man , Huiming Bao , Zhanyu Niu , Zhonghua Zhang , Jerine Peter Simon , Tong Yang , Pengtao Li , Shouliang Dong
{"title":"Multimodal profiling of Pepcan-CB1 receptor structure-activity relationships: integrating molecular dynamics simulations, biological profiling, and the deep learning model MuMoPepcan","authors":"Hongyang Man , Huiming Bao , Zhanyu Niu , Zhonghua Zhang , Jerine Peter Simon , Tong Yang , Pengtao Li , Shouliang Dong","doi":"10.1016/j.bioorg.2025.109027","DOIUrl":null,"url":null,"abstract":"<div><div>In machine learning of drug discovery, the scale of accessible data is often strictly limited, while few-shot learning in wet-lab experimental data limits the accuracy of machine learning algorithms. Cannabinoid receptors are involved in various important physiological activities, and pepcans are key components of the endocannabinoid system. Herein, we proposed a combined dry-wet lab experimental framework that incorporated molecular dynamics simulation (MDS) data into peptide biological activity prediction. We validated our hypothesis on cannabinoid receptors type 1 (CB1) and pepcans: (1) In the study, we synthesized 45 pepcan peptides to establish a bioactivity dataset and identified RD-pepcan-11 as an lead analgesic compound by Bioscreening, with systematic characterization of its CB1 selectivity and pharmacodynamics.; (2) Millions of conformational data were generated by MDS and a CB1-pepcans conformation dataset was constructed; (3) Combining wet-lab data and MDS data, a deep learning model - MuMoPepcan was developed, reducing prediction errors to within the error range of wet-lab experiments. This study not only identified novel high-potential pepcans - RD-pepcan-11, but also demonstrated that MDS can serve as an effective data augmentation method to scale up drug-receptor datasets, thereby improving model generalizability and performance.</div></div>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"165 ","pages":"Article 109027"},"PeriodicalIF":4.7000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioorganic Chemistry","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0045206825009071","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
In machine learning of drug discovery, the scale of accessible data is often strictly limited, while few-shot learning in wet-lab experimental data limits the accuracy of machine learning algorithms. Cannabinoid receptors are involved in various important physiological activities, and pepcans are key components of the endocannabinoid system. Herein, we proposed a combined dry-wet lab experimental framework that incorporated molecular dynamics simulation (MDS) data into peptide biological activity prediction. We validated our hypothesis on cannabinoid receptors type 1 (CB1) and pepcans: (1) In the study, we synthesized 45 pepcan peptides to establish a bioactivity dataset and identified RD-pepcan-11 as an lead analgesic compound by Bioscreening, with systematic characterization of its CB1 selectivity and pharmacodynamics.; (2) Millions of conformational data were generated by MDS and a CB1-pepcans conformation dataset was constructed; (3) Combining wet-lab data and MDS data, a deep learning model - MuMoPepcan was developed, reducing prediction errors to within the error range of wet-lab experiments. This study not only identified novel high-potential pepcans - RD-pepcan-11, but also demonstrated that MDS can serve as an effective data augmentation method to scale up drug-receptor datasets, thereby improving model generalizability and performance.
期刊介绍:
Bioorganic Chemistry publishes research that addresses biological questions at the molecular level, using organic chemistry and principles of physical organic chemistry. The scope of the journal covers a range of topics at the organic chemistry-biology interface, including: enzyme catalysis, biotransformation and enzyme inhibition; nucleic acids chemistry; medicinal chemistry; natural product chemistry, natural product synthesis and natural product biosynthesis; antimicrobial agents; lipid and peptide chemistry; biophysical chemistry; biological probes; bio-orthogonal chemistry and biomimetic chemistry.
For manuscripts dealing with synthetic bioactive compounds, the Journal requires that the molecular target of the compounds described must be known, and must be demonstrated experimentally in the manuscript. For studies involving natural products, if the molecular target is unknown, some data beyond simple cell-based toxicity studies to provide insight into the mechanism of action is required. Studies supported by molecular docking are welcome, but must be supported by experimental data. The Journal does not consider manuscripts that are purely theoretical or computational in nature.
The Journal publishes regular articles, short communications and reviews. Reviews are normally invited by Editors or Editorial Board members. Authors of unsolicited reviews should first contact an Editor or Editorial Board member to determine whether the proposed article is within the scope of the Journal.